Comparing two PSMA PET scans for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older.
- You must have prostate cancer that has spread (metastatic), and it must be either hormone-sensitive or castration-resistant.
- You must be generally active, able to care for yourself, and up and about more than half of your waking hours.
- A recent PSMA PET scan must show cancer lesions.
- Your blood test results must show adequate kidney and liver function, and a platelet count above 90.
- You must be expected to live at least 6 more months.
- If you are sexually active, you and your partner must use effective birth control during and for 3 months after the study, and you must not donate sperm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.